Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Individualized Prolonged Luteal Support After Fresh Embryo Transfer in Women With Low Progesterone (ProLIS)

29 maj 2026 uppdaterad av: University Hospital, Montpellier

Interest of Individualized Prolongation of Subcutaneous Luteal Phase Support up to 8 Weeks for Patients Pregnant After a Fresh Embryo Transfer and With Low Serum Progesterone Level at Pregnancy Test - a Multicentric Randomized Double Blinded Controlled Trial

The goal of this clinical trial is to compare live birth rate in a control group versus an interventional group in subjects aged 18 to 37, pregnant after a fresh embryo transfer and with a serum progesterone level below 17 ng/mL on the day of pregnancy test while using vaginal progesterone as a luteal support. .

This is the first randomized controlled trial to assess the benefit of prolonged subcutaneous progesterone administration in patients with a positive pregnancy test (Bêta chorionique gonadotropic hormone: β-hCG >100 IU/L) after fresh transfer and low progesterone level (<17 ng/mL).

Half the participants will be offered a an extension of luteal phase support , by subcutaneous progesterone supplementation for 6 weeks, the other half will have placebo injections. A double-blind, placebo-controlled, randomized design was chosen to prevent selection bias and ensure the comparability of both study arms.

Studieöversikt

Detaljerad beskrivning

Introduction:

Progesterone is essential for implantation and early pregnancy maintenance. After ovarian stimulation for In vitro fertilization (IVF), luteal phase insufficiency may occur, requiring luteal phase support (LPS) with exogenous progesterone. Recent data suggest that patients with low serum progesterone levels (<17 ng/mL) at positive pregnancy test after fresh embryo transfer have lower live birth rates and higher miscarriage rates despite standard vaginal LPS.

Aim:

The primary objective of the study is to compare live birth rates between:

  • a control group receiving standard luteal phase support with vaginal progesterone until pregnancy test and placebo subcutaneous injections until 8 weeks of gestation, and
  • an intervention group receiving prolonged luteal phase support with subcutaneous progesterone until 8 weeks of gestation.

Secondary objectives include comparison of clinical pregnancy rate, ongoing pregnancy rate, miscarriage rate, treatment-related adverse events, obstetrical and neonatal outcomes, gestational age at delivery, birth weight, and cost-effectiveness of the individualized prolonged luteal support strategy.

An ancillary biological sub-study conducted at Montpellier University Hospital will assess serum 17-hydroxyprogesterone and estradiol levels at inclusion.

Methods:

This study is a phase III, multicenter, randomized, double-blind, placebo-controlled trial.

Women aged 18-37 years with positive pregnancy test (Bêta chorionique gonadotropic hormone: β-hCG >100 IU/L) and serum progesterone <17 ng/mL after fresh embryo transfer will be randomized (1:1) to receive either:

  • subcutaneous progesterone (PROGIRON®) for 6 weeks, or
  • matching placebo for 6 weeks. To ensure adequate progesterone exposure during treatment initiation, vaginal progesterone (PROGESTAN®) will be continued for the first 4 days after randomization in both groups.

Participants will be followed until delivery. A total of 214 participants will be enrolled across multiple In vitro fertilization (IVF) centers.

Studietyp

Interventionell

Inskrivning (Beräknad)

214

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Patient aged 18 to 37 year-old;
  • Patients with a BMI below 34 kg/m2;
  • After a fresh embryo transfer following an ovarian hyperstimulation for an IVF with a luteal phase support based on micronized vaginal progesterone;
  • With a positive pregnancy test (β-hCG > 100 UI/L);
  • With a serum progesterone level below 17 ng/mL on the day of pregnancy test;
  • Patient able to self-administer subcutaneous progesterone injections, either alone or with the help of her partner.

Exclusion Criteria:

  • Patient undertaking an additional source of progesterone (oral or injected) or a treatment stimulating endogenous progesterone secretion (such as Gonadotropin-Releasing Hormone: GnRH agonist, or chorionique gonadotropic hormone: hCG injections);
  • Patients with intolerance or contraindication to subcutaneous progesterone administration;
  • Patients with a known 21-hydroxylase deficiency;
  • Patients with uterine pathology or untreated hydrosalpinx;
  • Patients with a history of recurrent miscarriages (3 or more);
  • Patient undergoing pre-implantation genetic testing;
  • Patient unavailable or unwilling to participate in future visits or is unable to comply with trial protocol;
  • Subjects unable to read or/and write French;
  • Failure to obtain the consent;
  • Subjects non-beneficiary of the French social security (Government medical aid (AME) excluded);
  • Subjects placed under legal protection, under guardianship or under curatorship;
  • Patient in an exclusion period determined by a previous study;
  • Subjects participating in another interventional research.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Placebo-jämförare: Control group

Discontinuation of luteal phase support with a subcutaneous placebo daily until 8 weeks of gestation (for 6 weeks).

Vaginal progesterone will be continued for 4 days after placebo initiation. Apart from these 4 days of transition treatment, the patient will not receive any additional treatment for luteal phase support (discontinuation of progesterone soft capsule administration according to the center's standard practice).

One injection of PLACEBO (identical in appearance to the PROGIRON® pre-filled syringe) per day will be administered until 8 weeks of gestation (Day 1 to Day 42).
Andra namn:
  • PLACEBO, injectable solution
Vaginal progesterone treatment with PROGESTAN® (200 mg 3 times daily) will be continued for 4 days after initiation of the investigational medicinal product (Day 1 to Day 4), pending achievement of stable progesterone serum concentrations with injectable progesterone.
Andra namn:
  • PROGESTAN 200 mg, vaginal soft capsule
Experimentell: Experimental group

Prolonged luteal phase support, switched to subcutaneous progesterone 25 mg daily until 8 weeks of gestation (for 6 weeks).

Vaginal progesterone will be continued for 4 days after subcutaneous progesterone initiation to ensure adequate serum levels while awaiting steady-state concentration of subcutaneous progesterone.

Apart from these 4 days of transition treatment, the patient will not receive any additional treatment for luteal phase support (discontinuation of progesterone soft capsule administration according to the center's standard practice).

Vaginal progesterone treatment with PROGESTAN® (200 mg 3 times daily) will be continued for 4 days after initiation of the investigational medicinal product (Day 1 to Day 4), pending achievement of stable progesterone serum concentrations with injectable progesterone.
Andra namn:
  • PROGESTAN 200 mg, vaginal soft capsule
One injection of PROGIRON® (25 mg pre-filled syringe) per day will be administered until 8 weeks of gestation (Day 1 to Day 42).
Andra namn:
  • PROGIRON 25 mg, injectable solution

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Live birth rate
Tidsram: At postpartum follow-up (Visit 4: Month 9 ±1 month)
Defined as a birth of at least one live born baby, weighing 500 g or more or 20 weeks or more of gestation, with the birth of twins counted as one live birth.
At postpartum follow-up (Visit 4: Month 9 ±1 month)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Clinical pregnancy rate
Tidsram: At first trimester follow-up (Visit 3: Week 12-14 of gestation)

Defined as ultrasound visualization of a gestational sac, excluding ectopic pregnancy.

Multiple gestational sacs in one participant will be counted as one clinical pregnancy

At first trimester follow-up (Visit 3: Week 12-14 of gestation)
Ongoing pregnancy rate
Tidsram: At first trimester follow-up (Visit 3: Week 12-14 of gestation)
Defined as a viable intrauterine pregnancy at ≥12 weeks of gestation.
At first trimester follow-up (Visit 3: Week 12-14 of gestation)
Miscarriage rate
Tidsram: From inclusion (Visit 1: positive pregnancy test or the following day) to 20 weeks of gestation
Defined as spontaneous pregnancy loss before 20 weeks of gestation, including early pregnancy loss (<12 weeks) and late pregnancy loss (12-20 weeks).
From inclusion (Visit 1: positive pregnancy test or the following day) to 20 weeks of gestation
Incidence of treatment-related adverse events
Tidsram: From inclusion (Visit 1: positive pregnancy test or the following day) to follow-up (Visit 2: Week 6-7 after test +)
Incidence of adverse events reported during the intervention period.
From inclusion (Visit 1: positive pregnancy test or the following day) to follow-up (Visit 2: Week 6-7 after test +)
Incidence of obstetrical and neonatal complications
Tidsram: At postpartum follow-up (Visit 4: Month 9 ±1 month)
Including premature rupture of membranes, preterm labor or delivery, fetal growth restriction, hypertensive disorders, pre-eclampsia, gestational diabetes, macrosomia, placental abnormalities, birth defects, stillbirth, perinatal death, and neonatal hospitalization.
At postpartum follow-up (Visit 4: Month 9 ±1 month)
Birth weight
Tidsram: At postpartum follow-up (Visit 4: Month 9 ±1 month)
Weight of the newborn at delivery.
At postpartum follow-up (Visit 4: Month 9 ±1 month)
Gestational age at delivery
Tidsram: At postpartum follow-up (Visit 4: Month 9 ±1 month)
Gestational age in weeks at the time of delivery.
At postpartum follow-up (Visit 4: Month 9 ±1 month)
Incremental cost-effectiveness ratio (ICER)
Tidsram: From inclusion (Visit 1: Positive pregnancy test or the following day) to postpartum follow-up (Visit 4: Month 9 ±1 month)
Cost-effectiveness analysis comparing prolonged subcutaneous progesterone versus placebo, with effectiveness defined by live birth rate.
From inclusion (Visit 1: Positive pregnancy test or the following day) to postpartum follow-up (Visit 4: Month 9 ±1 month)

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Serum 17-hydroxyprogesterone level
Tidsram: At inclusion (Visit 1: positive pregnancy test or the following day)
Sub-study objectives, only for participants from Montpellier University Hospital the serum levels of 17-hydroxy-progesterone (ng/mL) will be investigated on the day of inclusion.
At inclusion (Visit 1: positive pregnancy test or the following day)
Serum estradiol level
Tidsram: At inclusion (Visit 1: positive pregnancy test or the following day)
Sub-study objectives, only for participants from Montpellier University Hospital the serum levels of estradiol (pg/mL) will be investigated on the day of inclusion.
At inclusion (Visit 1: positive pregnancy test or the following day)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Noémie RANISAVLJEVIC, MD, PhD, University Hospital, Montpellier
  • Studiestol: Tal ANAHORY, MD, University Hospital, Montpellier

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 mars 2027

Primärt slutförande (Beräknad)

1 september 2029

Avslutad studie (Beräknad)

1 september 2030

Studieregistreringsdatum

Först inskickad

21 maj 2026

Först inskickad som uppfyllde QC-kriterierna

21 maj 2026

Första postat (Faktisk)

29 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

2 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

29 maj 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • RECHMPL_25_0581
  • 2026-525452-28-00 (Ctis)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera